Follow-up Studies, Satisfaction, Recurrence, Dosage and Drug Safety

  • David WarwickEmail author


Since CCH was approved by regulatory authorities, further data have emerged. CCH is, in the short term, effective in reducing cord contracture. Higher doses reduce the need for multiple injections on separate occasions but at the expense of increased skin splitting. Local anaesthetic prior to manipulation improves correction but increases the risk of skin splitting. Delayed manipulation allows more convenient scheduling. The relatively high risk of recurrence must be factored into a treatment algorithm. Patient satisfaction is high but may decline with time as the disease recurs. Side effects are common and occasionally alarming, but most are mild and resolve promptly. Clinically significant complications (allergic shock, tendon rupture) are rare. Further comparative information is required for efficacy, cost-effectiveness, satisfaction and recurrence. Because CCH is not suitable for all cords, randomised trials will be of limited value, and registry data are likely to be informative.


  1. 1.
    Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg [Am]. 2010;35:2027–38.CrossRefGoogle Scholar
  2. 2.
    Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361:968–79.CrossRefPubMedGoogle Scholar
  3. 3.
    Witthaut J, Jones G, Skrepnik N, Kushner H, Houston A, Lindau TR. Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg [Am]. 2013;38:2–11.CrossRefGoogle Scholar
  4. 4.
    Warwick D, Arner M, Pajardi G, Reichert B, Szabo Z, Masmejean EH, Fores J, Chapman DS, Gerber RA, Huard F, Seghouani A, Szczypa PP. Collagenase Clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur. 2015;40E:124–32.CrossRefGoogle Scholar
  5. 5.
    Warwick D, Graham D, Worley P. New insights into the immediate outcome of collagenase injections for Dupuytren’s contracture. J Hand Surg Eur. 2016;41:583–8.CrossRefGoogle Scholar
  6. 6.
    Bainbridge C, Gerber RA, Szczypa PP, Smith T, Kushner H, Cohen B, Hellio Le Graverand-Gastineau MP. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren’s contracture. J Plast Surg Hand Surg. 2012;46:177–83.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Denkler K. Collagenase for recurrent dupuytren contracture with skin grafts. J Hand Surg [Am]. 2013;38:1264.CrossRefGoogle Scholar
  8. 8.
    Dreise MM, Stenekes MW, Werker PM. Collagenase treatment for Dupuytren disease of the thumb and first web. J Hand Surg [Am]. 2016;41:348–53.CrossRefGoogle Scholar
  9. 9.
    Gaston RG, Larsen SE, Pess GM, Coleman S, Dean B, Cohen BM, Kaufman G, Tursi JP, Hurst LC. The efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 Dupuytren contractures in the same hand. J Hand Surg [Am]. 2015;40:1963–71.CrossRefGoogle Scholar
  10. 10.
    Kaplan TD, Badalamente M, Hurst L, et al. Delayed manipulation following Clostridial Collagenase histolyticum injection for Dupuytren contracture. J Hand Surg. 2013;38:52–3.CrossRefGoogle Scholar
  11. 11.
    Mickelson DT, Noland SS, Watt AJ, et al. Prospective RCT comparing 1-versus 7-day manipulation following collagenase injection for Dupuytren contracture. J Hand Surg. 2014;39:1933–41.CrossRefGoogle Scholar
  12. 12.
    Scherman P, Jenmalm P, Dahlin LB. One-year results of needle fasciotomy and collagenase injection in treatment of Dupuytren’s contracture: a two-centre prospective randomized clinical trial. J Hand Surg Eur. 2016;41:577–82.CrossRefGoogle Scholar
  13. 13.
    Stromberg J, Ibsen-Sorensen A, Friden J. Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomised, single blinded, clinical trial with a 1 year follow up. J Hand Surg [Am]. 2016;41:873–80.CrossRefGoogle Scholar
  14. 14.
    Zhou C, Hovius SE, Slijper HP, Feitz R, Van Nieuwenhoven CA, Pieters AJ, Selles RW. Collagenase Clostridium histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity score matched study. Plast Reconstr Surg. 2015;136:87–97.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhou C, Hovius S, Zuidam MJ, Smit X, Feitz R, Selles RW. Patient satisfaction with hand function after fasciectomy for Dupuytren’s contracture. Plast Reconstr Surg. 2016;138:649–55.CrossRefPubMedGoogle Scholar
  16. 16.
    Kan HJ, de Bekker-Grob EW, van Marion ES, van Oijen GW, van Nieuwenhoven CA, Zhou C, Hovius SE, Selles RW. Patients’ preferences for treatment for Dupuytren’s disease: a discrete choice experiment. Plast Reconstr Surg. 2016;137:165–73.CrossRefPubMedGoogle Scholar
  17. 17.
    Bradley J, Warwick D. Patient satisfaction with collagenase. J Hand Surg. 2016;41(A):689–97.CrossRefGoogle Scholar
  18. 18.
    Kan HJ, Verrijp FW, Huisstede BM, Hovius SE, van Nieuwenhoven CA, Selles RW. The consequences of different definitions for recurrence of Dupuytren’s disease. J Plast Reconstr Aesthet Surg. 2013;66:95–103.CrossRefPubMedGoogle Scholar
  19. 19.
    Felici N, Marcoccio I, Giunta R, Haerle M, Leclercq C, Pajardi G, Wilbrand S, Georgescu AV, Pess G. Dupuytren contracture recurrence project: reaching consensus on a definition of recurrence. Handchir Mikrochir Plast Chir. 2014;46:350–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP. Safety and tolerability of collagenase clostridium hystiolyticum and fasciectomy for Dupuytrens contracture. J Hand Surg Eur. 2014;40:141–9.CrossRefGoogle Scholar
  21. 21.
    Eberlin KR, Kobraei EM, Nyame TT, Bloom JM, Upton J. Salvage palmar fasciectomy after initial treatment with collagenase clostridium hystiolyticum. Plast Reconstr Surg. 2015;135:1000–6.CrossRefGoogle Scholar
  22. 22.
    Hay DC, Louie DL, Earp BE, Kaplan FT, Akelman E, Blazar PE, et al. Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase. J Hand Surg Eur. 2014;39:463–5.CrossRefGoogle Scholar
  23. 23.
    Peimer C, Blazar P, Coleman S, Kaplan T, Smith T, Lindau T. Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [collagenase option for reduction of Dupuytren long-term evaluation of safety study]): 5-year data. J Hand Surg. 2015;40:1597–605.CrossRefGoogle Scholar
  24. 24.
    Watt AJ, Curtin CM, Hentz VR. Collagenase injection as nonsurgical treatment of Dupuytren’s disease: 8-year follow-up. J Hand Surg [Am]. 2010;35:534–9.CrossRefGoogle Scholar
  25. 25.
    Atroshi I, Jesper Nordenskjöld J, Lauritzson A, Ahlgren E, Waldau J, Waldén M. Collagenase treatment of Dupuytren’s contracture using a modified injection A prospective cohort study of skin tears in 164 hands, including short-term outcome method. Acta Orthop. 2015;86:310–5.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Verheyden JR. Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique. J Hand Surg Eur. 2015;40:133–40.CrossRefGoogle Scholar
  27. 27.
    Peimer CA, McGoldrick CA, Greg Kaufman G. Nonsurgical treatment of Dupuytren contracture: 3-year safety results using collagenase Clostridium histolyticum. J Hand Surg [Am]. 2013;38:e52.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University Hospital SouthamptonSouthamptonUK
  2. 2.Faculty of MedicineUniversity of SouthamptonSouthamptonUK

Personalised recommendations